Swiss National Bank
RLMD icon

Swiss National Bank’s Relmada Therapeutics RLMD Stock Holding History

Swiss National Bank’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-53,300
Closed -$1.97M – 2717
2022
Q3 		$1.97M Buy
53,300
+6,600
+14% +$183K ﹤0.01% 1880
2022
Q2 		$887K Sell
46,700
-9,400
-17% -$205K ﹤0.01% 2433
2022
Q1 		$1.51M Buy
56,100
+4,100
+8% +$84.8K ﹤0.01% 2195
2021
Q4 		$1.17M Buy
52,000
+26,000
+100% +$578K ﹤0.01% 2383
2021
Q3 		$681K Buy
26,000
+900
+4% +$24.1K ﹤0.01% 2527
2021
Q2 		$803K Sell
25,100
-4,600
-15% -$160K ﹤0.01% 2544
2021
Q1 		$1.05M Buy
29,700
+700
+2% +$24.5K ﹤0.01% 2332
2020
Q4 		$930K Buy
29,000
+1,400
+5% +$48.1K ﹤0.01% 2328
2020
Q3 		$1.04M Buy
27,600
+1,000
+4% +$38.6K ﹤0.01% 2069
2020
Q2 		$1.19M Buy
+26,600
New +$1.12M ﹤0.01% 2006

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Swiss National Bank's RLMD Position: Q4 2022 in Review

Swiss National Bank sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 53,300 shares — an estimated $1.97M sold.

Swiss National Bank first reported a position in RLMD in Q2 2020 and held it in 10 quarters. The position peaked at $1.97M in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Swiss National Bank reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Swiss National Bank sold 53,300 Relmada Therapeutics shares in Q4 2022, an estimated $1.97M.
  • Swiss National Bank first reported a position in Relmada Therapeutics in Q2 2020 and held it in 10 quarters.
  • Swiss National Bank's Relmada Therapeutics position peaked at $1.97M in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Swiss National Bank's 13F filing for Q4 2022, filed 8 Feb 2023.